Currently Viewing:
The Academy of Managed Care Pharmacy (AMCP) 2018
Specialty Drug Pipeline Review Focuses on Competition, Cancer Drugs
April 24, 2018
Dr Robert Navarro Discusses Progress in Shift to Value-Based Care
April 24, 2018
Brian Litten Outlines How Medication Therapy Management Can Address Opioid Misuse
April 24, 2018
Who Decides What Value Looks Like in US Healthcare?
April 24, 2018
Dr Brandon Newman Discusses Payer, Academic Medical Center Collaboration
April 25, 2018
Dr Aimee Tharaldson Discusses Key Market Trends in Specialty Pharmacy
April 25, 2018
Migraines in the US Are More Than Just a Pain Problem
April 25, 2018
Market Access Teams Face New Challenges in Pharma
April 25, 2018
Cardiologist Talks About Value of Monoclonal Antibody Evolocumab
April 26, 2018
Dr Somali Burgess on the Role of Patient-Reported Outcomes in Managed Care Pharmacy
April 26, 2018
Dr Tina Joseph Discusses Collaborative Practice Agreements Between Pharmacists, Physicians
April 26, 2018
Navigating the Rocky Waters to Value-Based Healthcare
April 26, 2018
Hemophilia: Treatment Landscape, Costs, and Disease Management
April 26, 2018
Dr Aimee Tharaldson on Recently Approved Specialty Drugs, Upcoming Approvals to Watch
May 05, 2018
Dr Calvin Knowlton Outlines Benefits Seen From Enhanced Medication Therapy Management
May 06, 2018
The Rise of Orphan Drugs for Rare Diseases
May 07, 2018
Dr Robert Navarro Foresees Unintended Consequences From Shift to Value-Based Care
May 12, 2018
Dr Kimberly Lenz: Identifying Patients Most at Risk For Substance Abuse
May 13, 2018
Currently Reading
Brian Litten Outlines Challenges With Adopting Medication Therapy Management Services
May 17, 2018
Dr Calvin Knowlton on Innovative Practices in Enhanced Medication Therapy Management
May 20, 2018
Dr Ashley Pappas Discusses Collaboration Between Academic Centers and Payers
May 24, 2018
Dr Robert Navarro on Pharma Implementing Value, Best Practices for Value-Based Contracts
May 25, 2018
Drug Approvals That Dr Aimee Tharaldson Is Keeping an Eye on for 2019
May 27, 2018
Dr Kimberly Lenz on Implementing, Enforcing Appropriate Opioid Prescribing
June 04, 2018

Brian Litten Outlines Challenges With Adopting Medication Therapy Management Services

Brian Litten, JD, chief strategic officer, Tabula Rasa HealthCare, discusses how Medication Therapy Management (MTM) services work to improve health outcomes, challenges with the adoption of MTM services, and how CMMI's Enhanced MTM Model addresses these challenges.


Brian Litten, JD, chief strategic officer, Tabula Rasa HealthCare, discusses how Medication Therapy Management (MTM) services work to improve health outcomes, challenges with the adoption of MTM services, and how CMMI's Enhanced MTM Model addresses these challenges.

Transcript

How do Medication Therapy Management services work to improve health outcomes? Are there any challenges with the adoption of these services?

Medication Therapy Management (MTM) is a suite of clinical services provided by a pharmacist to help doctors and patients with their medication regimens—to optimize the safety of their medications and have better outcomes.

So, there are 3 components of MTM. One identification, one is engagement, and one is intervention. The identification phase is where a health plan, primarily a payer, will identify a cohort of patients who they believe—or in the case of Part D the government believes—will benefit most from MTM services. The identification part is the easy part. The second part is engagement. That’s a little bit more tricky. In the engagement phase, MTM providers, vendors, need to work to establish trusted relationships with patients and with doctors. Doctors have very busy workflows and significant demands upon them. Patients tend to be cynical about strangers calling them to talk about health issues. So that’s a big challenge.

On the intervention side, once you get that trust and you’re able to have that success of gaining the patient’s and doctor’s trust, having a real conversation about the risks that have been identified and the steps that can be taken to reduce the risk provide results.

Another significant challenge is that, historically, since Part D adopted MTM as a requirement back in the Medicare Modernization Act of 2003, it has become, overtime, just a process driven event. It’s measured in terms of completion rates—how many patients are eligible for MTM services and out of those patients, how many of them have had a Comprehensive Medication Review. Plans are measured on process, rather than on quality, and that’s where the whole purpose of MTM really has been lost.

How does CMMI’s Enhanced Medication Therapy Management Model address these challenges?

The enhanced MTM model is a recognition on the part of the government that traditional MTM, which is process driven, doesn’t provide adequate incentives to health plans to really do what MTM is supposed to do, which is drive better results. So, in the enhanced MTM program, the government has removed—for those plans participating in the 5-year model—the regulatory requirements, the completion rates, all of the administrative burdens that have grown up around MTM in the Part D space, and they’ve charged the plans to innovate.

They’ve said, quite specifically, be as creative as you can be, and figure out how to make this work. What work means is to use MTM, the suite of services that pharmacists provide to doctors and patients, to have an impact on therapeutic outcomes. They’ll be measured, instead of on completion rates, instead of on process, they’ll be measured on reducing actual medical expenditures. The success of the program will be determined on their ability to do that.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up